Skip to main content
. 2017 Aug 21;14(10):3457–3463. doi: 10.1021/acs.molpharmaceut.7b00464

Figure 4.

Figure 4

Autoradiography (a) and fluorescence imaging (b) of a tissue section of the mouse oviduct revealed an area with high accumulation of dual-labeled farletuzumab. H&E staining (c) of this same tissue section showed that this area corresponded with a 0.25 mm tumor lesion located near the oviduct. The FRα-staining on an adjacent tissue section confirmed that this lesion expressed FRα (d).